Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term use and risk of major adverse cardiac events: Comparing enzalutamide and abiraterone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.
Chen HK, Su PJ, Wang YL, Chang KC, Su YL, Chang PH, Kuan FC, Hsieh CH, Kuo YC, Sheng TW, Chang CF, Yu SM, Huang WK, Lin YC, Tsan DL, Yu KJ, Lin PH, Chen HY, Chang YH, Pang ST, Chuang CK, Lai EC. Chen HK, et al. Among authors: su pj, su yl. Int J Cancer. 2023 Mar 15;152(6):1191-1201. doi: 10.1002/ijc.34348. Epub 2022 Dec 9. Int J Cancer. 2023. PMID: 36346116 Free article.
Definitive concurrent chemoradiotherapy with paclitaxel plus carboplatin is superior to cisplatin plus 5-fluorouracil in patients with inoperable esophageal squamous cell carcinoma using retrospective, real-world evidence.
Hsieh JC, Chiang PC, Hung TM, Chao YK, Kuo YC, Wen CT, Su PJ, Peng MT, Chen HW, Liu HL, Chang HK, Wu MH, Wang HM. Hsieh JC, et al. Among authors: su pj. Cancer Med. 2021 Dec;10(23):8300-8309. doi: 10.1002/cam4.4025. Epub 2021 Oct 27. Cancer Med. 2021. PMID: 34706159 Free PMC article.
Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study.
Chen DY, Su PJ, See LC, Liu JR, Chuang CK, Pang ST, Tseng CN, Chen SW, Hsieh IC, Chu PH, Lin YC, Hsu CL, Chang JW, Lin MS, Pang JS, Hsieh MJ, Huang WK. Chen DY, et al. Among authors: su pj. Prostate. 2021 Sep;81(12):902-912. doi: 10.1002/pros.24187. Epub 2021 Jul 1. Prostate. 2021. PMID: 34196430
First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis.
Lin CT, Su PJ, Huang SY, Wu CC, Wang HJ, Cheng YT, Luo HL, Chen CH, Liu TT, Huang CC, Su YL. Lin CT, et al. Among authors: su pj, su yl. J Immunother. 2022 Nov-Dec 01;45(9):407-414. doi: 10.1097/CJI.0000000000000441. Epub 2022 Sep 20. J Immunother. 2022. PMID: 36121316 Free PMC article.
A cost-effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan.
Su PJ, Xiao Y, Lin AY, Goh C, Wu E, Liu K, Chou P, Kuo K, Palencia R, Chang J, Kearney M, Kapetanakis V, Benedict A. Su PJ, et al. Cancer Rep (Hoboken). 2023 Oct;6(10):e1887. doi: 10.1002/cnr2.1887. Epub 2023 Aug 28. Cancer Rep (Hoboken). 2023. PMID: 37640556 Free PMC article.
77 results